Cat. No. 2276
Chemical Name: 7-[3-(4-Acetyl-3-hydroxy-2-propylph
Biological ActivityLeukotriene receptor antagonist; inhibits contraction of guinea pig trachealis induced by leukotrienes C4, D4, E4 and F4.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Folkerts et al (1995) Leukotrienes mediate tracheal hyperresponsiveness after nitric oxide synthesis inhibition. Eur.J.Pharmacol. 285 R1. PMID: 8566126.
O'Donnell and Welto (1984) Pharmacologic properties of FPL 55712 administered by aerosol. Agents Actions 14 43. PMID: 6322547.
Jones et al (1983) Pharmacological study of the effects of leukotrienes C4, D4, E4 & F4 on guinea pig trachealis: interaction with FPL-55712. Prostaglandins 26 833. PMID: 6322240.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses FPL 55712 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: FPL 55712, supplier, leukotrienes, eicosanoids, receptor, antagonists, CysLT1, Receptors, receptors, LTD4, LTE4, FPL55712, Tocris Bioscience, Leukotriene and Related Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Selective GPR84 agonistIHR-Cy3
Potent fluorescent Smo antagonistRo 6842262
Potent LPA1 antagonistAMG 853
Potent dual CRTH2 and prostaglandin D2 (PGD2) receptor antagonistAM 4668
Potent FFA1 (GPR40) agonistCATPB
FFA2 antagonist/inverse agonistOleanolic acid
Selective GPBA receptor (TGR5) partial agonistPPTN hydrochloride
High affinity and selective P2Y14 antagonistItraconazole
SMO antagonist; acts at different binding site to cyclopamine (Cat No. 1623)SAR 216471 hydrochloride
Potent P2Y12 antagonist; orally available
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.